SAN CARLOS, Calif.--(BUSINESS WIRE)--Nov. 3, 2005--Nektar Therapeutics (Nasdaq:NKTR): Exubera(R) receives positive recommendations in Europe and US; FDA extends review period by 3 months; Two proprietary products in clinic address unmet need for prevention of lung infections; New high-value Baxter agreement to develop PEGylated therapeutic forms of blood clotting proteins; Chiron and Nektar advance TIP to Phase III; Aerogen acquisition broadens Nektar pulmonary leadership; Company strengthens balance sheet.
